HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,350.00
-30.00 (-0.89%)
Sep 29, 2025, 3:30 PM KST
-69.55%
Market Cap 411.84B
Revenue (ttm) 108.93B
Net Income (ttm) -77.70B
Shares Out 121.85M
EPS (ttm) -654.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 210,633
Average Volume 353,820
Open 3,375.00
Previous Close 3,380.00
Day's Range 3,350.00 - 3,450.00
52-Week Range 3,285.00 - 11,940.00
Beta -0.33
RSI 32.86
Earnings Date Nov 13, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.